How multimodal treatment affects tumor cells in the blood of people with rectal cancer.
The Effect of Multimodal Treatment of Rectal Cancer on Circulating Tumor Cells: A Prospective, Observational Study
This study will see if multimodal treatment changes levels of circulating tumor cells in people with rectal cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Institute of Molecular and Translational Medicine, Czech Republic Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Ostrava) |
| Trial ID | NCT07112937 on ClinicalTrials.gov |
What this trial studies
Researchers will prospectively collect peripheral blood samples from rectal cancer patients at predefined time points during their multimodal therapy to measure circulating tumor cells (CTCs). The observational protocol compares CTC counts in patients who receive neoadjuvant chemoradiotherapy with those who do not. No experimental treatments are assigned and clinical care follows standard practice while samples are analyzed to track changes over time. The study excludes patients with other active cancers and is conducted at University Hospital Ostrava in the Czech Republic.
Who should consider this trial
Good fit: Adults with a diagnosis of rectal cancer who are undergoing multimodal treatment and can provide serial blood samples are ideal candidates.
Not a fit: Patients with other active cancers, those not receiving multimodal therapy, or those unable to attend the site for serial blood draws are unlikely to receive benefit from participation.
Why it matters
Potential benefit: If successful, the findings could help doctors use CTC levels to monitor treatment response or inform future personalized care for rectal cancer patients.
How similar studies have performed: Previous colorectal cancer research has shown CTC counts can correlate with prognosis, but using CTC monitoring to guide rectal cancer treatment decisions remains experimental.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: rectal cancer - Exclusion Criteria: no other cancer \-
Where this trial is running
Ostrava
- University Hospital Ostrava — Ostrava, Czechia (Recruiting)
Study contacts
- Study coordinator: Josef Srovnal, Associate professor, MD, PhD
- Email: josef.srovnal@upol.cz
- Phone: +420 585632137
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.